Phase II Study to Evaluate Safety and Efficacy of Neratinib, an Irreversible Pan-Her Tyrosine Kinase Inhibitor, and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid Tumors (KCSG AL20-17).
JOURNAL OF CLINICAL ONCOLOGY（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined